Ventyx Biosciences Inc

VTYX

Equity

ISIN null / Valor 114064386

NASDAQ (2025-11-21)

USD 9.43-1.87%

Ventyx Biosciences Inc
UMushroom community rating:

4.00 4 votes No rating yet

NegativeNeutralPositive

About company

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company specializing in the development of novel oral therapies for patients with autoimmune and inflammatory disorders. The company's pipeline includes various promising drug candidates such as VTX958, VTX002, VTX2735, and VTX3232, targeting different mechanisms to address a broad range of autoimmune diseases. Ventyx is dedicated to advancing innovative treatments to improve the lives of patients suffering from these debilitating conditions.

Summarized from source with an LLMView SourceSector: Healthcare

Strong Cash Position

As of March 31, 2025, Ventyx Biosciences Inc maintained cash, cash equivalents, and marketable securities totaling $228.8 million, which is expected to fund planned operations into at least the second half of 2026.

Reduced Research and Development Expenses

Research and development expenses for the first quarter of 2025 were $22.9 million, a decrease from $33.7 million in the first quarter of 2024, reflecting improved cost management in ongoing projects.

Lower General and Administrative Costs

General and administrative expenses were $7.2 million for the first quarter of 2025, down from $8.0 million in the same quarter of the previous year, indicating efficient administrative operations.

Decreased Net Loss

The net loss for Ventyx Biosciences Inc in the first quarter of 2025 was $27.4 million, compared to a net loss of $38.6 million in the first quarter of 2024, demonstrating progress towards financial sustainability.

Summarized from source with an LLMView Source

Key figures

445%1Y

-64.2%3Y

%5Y

Performance

96.4%1Y

136%3Y

129%5Y

Volatility